Search

Your search keyword '"Kagawa, Y."' showing total 2,305 results
Start Over Author "Kagawa, Y."
2,305 results on '"Kagawa, Y."'

1. Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY

Author

Kataoka, K., Mori, K., Nakamura, Y., Watanabe, J., Akazawa, N., Hirata, K., Yokota, M., Kato, K., Kotaka, M., Yamazaki, K., Kagawa, Y., Mishima, S., Ando, K., Miyo, M., Yukami, H., Laliotis, G., Sharma, S., Palsuledesai, C.C., Rabinowitz, M., Jurdi, A., Liu, M.C., Aleshin, A., Kotani, D., Bando, H., Taniguchi, H., Takemasa, I., Kato, T., Yoshino, T., and Oki, E.

Published
2024
Full Text
View/download PDF

6. Recurrence monitoring using ctDNA in patients with metastatic colorectal cancer: COSMOS-CRC-03 and AURORA studies

Author

Oki, E., primary, Nakanishi, R., additional, Ando, K., additional, Takemasa, I., additional, Watanabe, J., additional, Matsuhashi, N., additional, Kato, T., additional, Kagawa, Y., additional, Kotaka, M., additional, Hirata, K., additional, Sugiyama, M., additional, Kusumoto, T., additional, Miyamoto, Y., additional, Toyosaki, K., additional, Kishimoto, J., additional, Kimura, Y., additional, Yoshizumi, T., additional, and Nakamura, Y., additional

Published
2024
Full Text
View/download PDF

11. Many-field theory for crystals containing particles with rotational degrees of freedom

Author

Dmitriev, S. V., Vasiliev, A. A., Miroshnichenko, A. E., Shigenari, T., Liu, Y., Kagawa, Y., and Ishibashi, Y.

Subjects
Condensed Matter - Materials Science
Abstract

We give a brief review of some generalized continuum theories applied to the crystals with complicated microscopic structure. Three different ways of generalization of the classical elasticity theory are discussed. One is the high-gradient theory, another is the micropolar type theory and the third one is the many-field theory. The importance of the first two types of theories has already been established, while the theory of the third type still has to be developed. With the use of 1D and 2D examples we show for each of these theories where they can be and should be applied, separately or in a combination., Comment: 15 pages, 2 figures

Published
2002

12. Phase III trial of short-course radiotherapy followed by CAPOXIRI versus CAPOX in locally advanced rectal cancer: the ENSEMBLE trial

Author

Watanabe, J., primary, Kagawa, Y., additional, Chida, K., additional, Ando, K., additional, Kotani, D., additional, Oba, K., additional, Bando, H., additional, Hojo, H., additional, Shimamoto, S., additional, Sakashita, S., additional, Kuwata, T., additional, Tsuboyama, T., additional, Hosomi, N., additional, Uemura, M., additional, Uehara, K., additional, Ito, M., additional, Oki, E., additional, Takemasa, I., additional, Misugi, E., additional, Sledge, G., additional, Sumani, K., additional, Imoto, S., additional, Kato, T., additional, and Yoshino, T., additional

Published
2023
Full Text
View/download PDF

16. Peripheral Administration of the Kv1.3-Blocking Peptide HsTX1[R14A] Improves Cognitive Performance in Senescence Accelerated SAMP8 Mice

Author

Pan, Y, Kagawa, Y, Sun, J, Lucas, DSD, Takechi, R, Mamo, JCL, Wai, DCC, Norton, RS, Jin, L, Nicolazzo, JA, Pan, Y, Kagawa, Y, Sun, J, Lucas, DSD, Takechi, R, Mamo, JCL, Wai, DCC, Norton, RS, Jin, L, and Nicolazzo, JA

Abstract

Increased expression of the voltage-gated potassium channel Kv1.3 in activated microglia, and the subsequent release of pro-inflammatory mediators, are closely associated with the progression of Alzheimer's disease (AD). Studies have shown that reducing neuroinflammation through the non-selective blockade of microglial Kv1.3 has the potential to improve cognitive function in mouse models of familial AD. We have previously demonstrated that a potent and highly-selective peptide blocker of Kv1.3, HsTX1[R14A], not only entered the brain parenchyma after peripheral administration in a lipopolysaccharide (LPS)-induced mouse model of inflammation, but also significantly reduced pro-inflammatory mediator release from activated microglia. In this study, we show that microglial expression of Kv1.3 is increased in senescence accelerated mice (SAMP8), an animal model of sporadic AD, and that subcutaneous dosing of HsTX1[R14A] (1 mg/kg) every other day for 8 weeks provided a robust improvement in cognitive deficits in SAMP8 mice. The effect of HsTX1[R14A] on the whole brain was assessed using transcriptomics, which revealed that the expression of genes associated with inflammation, neuron differentiation, synapse function, learning and memory were altered by HsTX1[R14A] treatment. Further study is required to investigate whether these changes are downstream effects of microglial Kv1.3 blockade or a result of alternative mechanisms, including any potential effect of Kv1.3 blockade on other brain cell types. Nonetheless, these results collectively demonstrate the cognitive benefits of Kv1.3 blockade with HsTX1[R14A] in a mouse model of sporadic AD, demonstrating its potential as a therapeutic candidate for this neurodegenerative disease.

Published
2023

17. Reporting of adverse events related to dietary supplements to a public health center by medical staff: a survey of clinics and pharmacies

Author

Ide K, Yamada H, Kawasaki Y, Noguchi M, Kitagawa M, Chiba T, Kagawa Y, and Umegaki K

Subjects
Dietary supplements, complementary medicine, pharmacy practice, government regulations, survey, Therapeutics. Pharmacology, RM1-950
Abstract

Kazuki Ide,1 Hiroshi Yamada,1 Yohei Kawasaki,1 Marika Noguchi,1 Mamoru Kitagawa,1 Tsuyoshi Chiba,2 Yoshiyuki Kagawa,3 Keizo Umegaki2 1Department of Drug Evaluation & Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, 2Information Center, National Institutes of Biomedical Innovation, Health and Nutrition, Tokyo, 3Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan Background: Dietary supplements are used by >50% of the adult population in Japan, and adverse events related to these products have been reported with their increased use. Thus, an efficient system to gather and report data on these adverse events is essential. To date, however, reporting has been limited. The aim of this study was to address this deficiency by exploring the routine reporting practices of the medical staff employed at clinics or pharmacies in Japan.Methods: We conducted a survey of the procedures used by the medical staff to report adverse events related to dietary supplement intake to public health centers in Japan. The survey was conducted in Japan between November 2015 and January 2016. Based on a sample size calculation, questionnaires were administered to 1,700 potential respondents (850 pharmacists and 850 physicians). The questionnaire inquired about the sociodemographic characteristics and dietary supplement-related adverse event-reporting practices.Results: The response rate was 34.7%, including 286 pharmacists and 304 physicians. Although >30% of the pharmacists and physicians had prior experience dealing with such adverse events,

Published
2016

19. OA07.03 Association Between Genetic Variation in the ATP-binding Cassette Transporter ABCC10 and nab-PTX Treatment in Japanese Cohort

Author

Horiuchi, M., primary, Uemura, T., additional, Suzuki, Y., additional, Kagawa, Y., additional, Fukuda, S., additional, Maeno, K., additional, Oguri, T., additional, Mori, Y., additional, Sone, K., additional, Takeda, N., additional, Fukumitsu, K., additional, Kanemitsu, Y., additional, Tajiri, T., additional, Ohkubo, H., additional, Ito, Y., additional, and Niimi, A., additional

Published
2022
Full Text
View/download PDF

20. 442TiP A multicenter phase II clinical study evaluating the efficacy and safety of perioperative encorafenib, binimetinib plus cetuximab combination treatment in patients with surgically resectable BRAF V600E-mutant colorectal oligometastases (NEXUS)

Author

Kobayashi, S., primary, Bando, H., additional, Taketomi, A., additional, Takamoto, T., additional, Shinozaki, E., additional, Shiozawa, M., additional, Hara, H., additional, Yamazaki, K., additional, Komori, K., additional, Matsuhashi, N., additional, Kato, T., additional, Kagawa, Y., additional, Yokota, M., additional, Oki, E., additional, Takahashi, S., additional, and Yoshino, T., additional

Published
2022
Full Text
View/download PDF

21. 440TiP TRESBIEN (OGSG 2101): Encorafenib, binimetinib and cetuximab for early relapse stage II/III BRAF V600E-mutated CRC

Author

Boku, S., primary, Satake, H., additional, Ohta, T., additional, Mitani, S., additional, Kawakami, K., additional, Matsumoto, T., additional, Yamazaki, E., additional, Hasegawa, H., additional, Ikoma, T., additional, Uemura, M., additional, Yamaguchi, T., additional, Ishizuka, Y., additional, Kurokawa, Y., additional, Sakai, D., additional, Kawakami, H., additional, Shimokawa, T., additional, Tsujinaka, T., additional, Kato, T., additional, Satoh, T., additional, and Kagawa, Y., additional

Published
2022
Full Text
View/download PDF

25. P-76 Phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD)

Author

Sugimoto, N., primary, Nakata, K., additional, Miyo, M., additional, Yoshioka, S., additional, Kagawa, Y., additional, Naito, A., additional, Tei, M., additional, Tamagawa, H., additional, Konishi, K., additional, Osawa, H., additional, Shingai, T., additional, Danno, K., additional, Nishida, N., additional, Sato, G., additional, Shimokawa, T., additional, Miyoshi, N., additional, Takahashi, H., additional, Uemura, M., additional, Yamamoto, H., additional, Murata, K., additional, Doki, Y., additional, and Eguchi, H., additional

Published
2022
Full Text
View/download PDF

26. PD-13 Plasma RAS dynamics and efficacy of anti-EGFR rechallenge in patients with RAS/BRAF wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials

Author

Kagawa, Y., primary, Kotani, D., additional, Bando, H., additional, Takahashi, N., additional, Horita, Y., additional, Kanazawa, A., additional, Kato, T., additional, Ando, K., additional, Satake, H., additional, Shinozaki, E., additional, Sunakawa, Y., additional, Takashima, A., additional, Yamazaki, K., additional, Yuki, S., additional, Nakajima, H., additional, Nakamura, Y., additional, Wakabayashi, M., additional, Taniguchi, H., additional, Ohta, T., additional, and Yoshino, T., additional

Published
2022
Full Text
View/download PDF

27. P-80 A multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab and FOLFOXIRI plus bevacizumab as the first-line treatment for metastatic colorectal cancer: A safety analysis of the QUATTRO-II study

Author

Masuishi, T., primary, Bando, H., additional, Satake, H., additional, Kotani, D., additional, Hamaguchi, T., additional, Shiozawa, M., additional, Ikumoto, T., additional, Kagawa, Y., additional, Yasui, H., additional, Moriwaki, T., additional, Kawakami, H., additional, Boku, S., additional, Oki, E., additional, Komatsu, Y., additional, Taniguchi, H., additional, Muro, K., additional, Kotaka, M., additional, Yamazaki, K., additional, Misumi, T., additional, Yoshino, T., additional, Kato, T., additional, and Tsuji, A., additional

Published
2022
Full Text
View/download PDF

30. Altered Blood-Brain Barrier Dynamics in the C9orf72 Hexanucleotide Repeat Expansion Mouse Model of Amyotrophic Lateral Sclerosis

Author

Pan, Y, Kagawa, Y, Sun, J, Turner, BJ, Huang, C, Shah, AD, Schittenhelm, RB, Nicolazzo, JA, Pan, Y, Kagawa, Y, Sun, J, Turner, BJ, Huang, C, Shah, AD, Schittenhelm, RB, and Nicolazzo, JA

Abstract

For peripherally administered drugs to reach the central nervous system (CNS) and treat amyotrophic lateral sclerosis (ALS), they must cross the blood-brain barrier (BBB). As mounting evidence suggests that the ultrastructure of the BBB is altered in individuals with ALS and in animal models of ALS (e.g., SOD1G93A mice), we characterized BBB transporter expression and function in transgenic C9orf72 BAC (C9-BAC) mice expressing a hexanucleotide repeat expansion, the most common genetic cause of ALS. Using an in situ transcardiac brain perfusion technique, we identified a 1.4-fold increase in 3H-2-deoxy-D-glucose transport across the BBB in C9-BAC transgenic (C9) mice, relative to wild-type (WT) mice, which was associated with a 1.3-fold increase in brain microvascular glucose transporter 1 expression, while other general BBB permeability processes (passive diffusion, efflux transporter function) remained unaffected. We also performed proteomic analysis on isolated brain microvascular endothelial cells, in which we noted a mild (14.3%) reduction in zonula occludens-1 abundance in C9 relative to WT mice. Functional enrichment analysis highlighted trends in changes to various BBB transporters and cellular metabolism. To our knowledge, this is the first study to demonstrate altered BBB function in a C9orf72 repeat expansion model of ALS, which has implications on how therapeutics may access the brain in this mouse model.

Published
2022

40. P130 Comparison of the clinical course of Ulcerative Colitis according to the presence or absence of clinical symptoms at the time of diagnosis

Author

Madarame, A, primary, Fukuzawa, M, additional, Uchida, K, additional, Nemoto, D, additional, Shinohara, H, additional, Yamanishi, F, additional, Matsumoto, S, additional, Suzuki, Y, additional, Muramatsu, T, additional, Kagawa, Y, additional, Matsumoto, T, additional, Morise, T, additional, Yamaguchi, H, additional, Sugimoto, A, additional, Kono, S, additional, Yamauchi, Y, additional, Naito, S, additional, Kawai, T, additional, and Itoi, T, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results